Stefanie L. Vogt

Stefanie L. Vogt

Auto-generated profile, based on publicly available information

Stefanie L. Vogt

Michael Smith Laboratories, University of British Columbia, Vancouver, BC, Canada

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2011 in FEMS Microbiology Letters
Verified
Journal Article
Open access
PDF file
SVStefanie L. Vogt
Stefanie L. Vogt
TRTracy L. Raivio
Tracy L. Raivio
To detect and effectively respond to damage to the cell envelope, Gram-negative bacteria possess multiple envelope stress responses. Among these, the


26 April 2022 in Cell Reports
Verified
Journal Article
Open access
ASAntonio Serapio-Palacios
Antonio Serapio-Palacios
SWSarah E. Woodward
Sarah E. Woodward
SVStefanie L. Vogt
Stefanie L. Vogt
WDWanyin Deng
Wanyin Deng
ACAnna Creus-Cuadros
Anna Creus-Cuadros
BFB. Brett Finlay
B. Brett Finlay
The type VI secretion system (T6SS) is a contractile nanomachine widely distributed among pathogenic and commensal Gram-negative bacteria. The T6SS is used for inter-bacterial competition to directly kill competing species; however, its importance during bacterial infection in vivo remains poorly understood. We report that the murine pathogen Citrobacter rodentium, used as a model for human pathogenic Escherichia coli, harbors two functional T6SSs. C. rodentium employs its T6SS-1 to colonize the murine gastrointestinal tract by targeting commensal Enterobacteriaceae. We identify VgrG1 as a C. rodentium T6SS antibacterial effector, which exhibits toxicity in E. coli. Conversely, commensal prey species E. coli Mt1B1 employs two T6SSs of its own to counter C. rodentium colonization. Collectively, these data demonstrate that the T6SS is a potent weapon during bacterial competition and is used by both invading pathogens and resident microbiota to fight for a niche in the hostile gut environment.

1 October 2011 in Infection and Immunity
Verified
Journal Article
Closed access
PDF file
SVStefanie L. Vogt
Stefanie L. Vogt
CGChristopher Green
Christopher Green
KSKatarzyna M. Stevens
Katarzyna M. Stevens
BDBrad Day
Brad Day
DEDavid L. Erickson
David L. Erickson
DSDouglas G. Storey
Douglas G. Storey
The stringent response is a regulatory system that allows bacteria to sense and adapt to nutrient-poor environments. The central mediator of the stringent response is the molecule guanosine 3′,5′-bispyrophosphate (ppGpp), which is synthesized by the enzymes RelA and SpoT and which is also degraded by SpoT. Our laboratory previously demonstrated that arelAmutant ofPseudomonas aeruginosa, the principal cause of lung infections in cystic fibrosis patients, was attenuated in virulence in aDrosophila melanogasterfeeding model of infection. In this study, we examined the role ofspoTinP. aeruginosavirulence. We generated an insertion mutation inspoTwithin the previously constructedrelAmutant, thereby producing a ppGpp-devoid strain. TherelA spoTdouble mutant was unable to establish a chronic infection inD. melanogasterand was also avirulent in the rat lung agar bead model of infection, a model in which therelAmutant is fully virulent. Synthesis of the virulence determinants pyocyanin, elastase, protease, and siderophores was impaired in therelA spoTdouble mutant. This mutant was also defective in swarming and twitching, but not in swimming motility. TherelA spoTmutant and, to a lesser extent, therelAmutant were less able to withstand stresses such as heat shock and oxidative stress than the wild-type strain PAO1, which may partially account for the inability of therelA spoTmutant to successfully colonize the rat lung. Our results indicate that the stringent response, and SpoT in particular, is a crucial regulator of virulence processes inP. aeruginosa.

1 April 2017 in Journal of Travel Medicine
Verified
Journal Article
Open access
PDF file
SVStefanie L. Vogt
Stefanie L. Vogt
BFB. Brett Finlay
B. Brett Finlay
Background: The mammalian gut microbiota is a highly abundant and diverse microbial community that resides in the gastrointestinal tract. One major benefit that the gut microbiota provides to its host is colonization resistance—the ability to prevent colonization by foreign microbes, including diarrheal pathogens such as Clostridium difficile, Salmonella enterica serovar Typhimurium and diarrheagenic Escherichia coli. Methods: We conducted a literature review of the effects of the gut microbiota on infection by diarrheal pathogens. We used PubMed to search for relevant articles published before July 2016, as well as incorporated data from our laboratory. Results: The gut microbiota provides protection from diarrheal infections both by direct inhibition of pathogens and by indirect effects on host functions. Direct effects of the microbiota on diarrheal pathogens include competing for nutrients and producing metabolites that inhibit pathogen growth or virulence. Indirect effects of the gut microbiota include promoting maintenance of the gut mucosal barrier and stimulating innate and adaptive immunity. Conclusions: Human epidemiological studies and experimental infections of laboratory animals both demonstrate that antibiotic treatment can alter the gut microbial community and thereby reduce colonization resistance against diarrheal pathogens. Further research might lead to the development of next-generation probiotics that could be used to bolster colonization resistance and thus prevent travellers’ diarrheal. Introduction

23 November 2014 in Annual Review of Genetics
Verified
Journal Article
Closed access
SYSophie Yurist-Doutsch
Sophie Yurist-Doutsch
MAMarie-Claire Arrieta
Marie-Claire Arrieta
SVStefanie L. Vogt
Stefanie L. Vogt
BFB. Brett Finlay
B. Brett Finlay
The gastrointestinal (GI) microbiota is a complex community of microorganisms residing within the mammalian gastrointestinal tract. The GI microbiota is vital to the development of the host immune system and plays a crucial role in human health and disease. The composition of the GI microbiota differs immensely among individuals yet specific shifts in composition and diversity have been linked to inflammatory bowel disease, obesity, atopy, and susceptibility to infection. In this review, we describe the GI microbiota and its role in enteric diseases caused by pathogenic Escherichia coli, Salmonella enterica, and Clostridium difficile. We discuss the central role of the GI microbiota in protective immunity, resistance to enteric pathogens, and resolution of enteric colitis.